BXRX:NSD-Baudax Bio, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.50

Change

+0.06 (+4.17)%

Market Cap

USD 0.10B

Volume

3.84M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-5.38 (-3.58%)

USD59.42B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+0.60 (+0.28%)

USD56.27B 21.03 14.64
REGN Regeneron Pharmaceuticals, Inc

-9.43 (-2.01%)

USD50.14B 15.34 12.06
ALXN Alexion Pharmaceuticals, Inc

+1.56 (+1.02%)

USD33.62B 56.22 34.28
BGNE BeiGene, Ltd

+2.43 (+0.73%)

USD32.08B N/A N/A
RPRX Royalty Pharma plc

+0.28 (+0.60%)

USD29.34B 22.60 14.73
SGEN Seagen Inc

-2.01 (-1.28%)

USD28.45B 46.60 41.48
BNTX BioNTech SE

+2.20 (+1.96%)

USD27.59B -99,999.99 N/A
GMAB Genmab A/S

-1.57 (-4.28%)

USD25.02B 26.59 2.93
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BXRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 42.86% 74% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.86% 74% C 82% B-
Trailing 12 Months  
Capital Gain -79.34% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -79.34% 1% F N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -15.95% 19% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.95% 19% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 32.37% 81% B- 45% F
Risk Adjusted Return -49.28% 17% F 12% F
Market Capitalization 0.10B 16% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 84% B 99% A+
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -2.29 16% F 57% F
EV/EBITDA 0.23 60% D- 94% A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 668.69% 99% A+ 100% A+
Return on Assets -55.01% 13% F 4% F
Debt to Equity Ratio -57.23% 91% A- 94% A
Technical Ratios  
Short Ratio 0.44 81% B- 78% C+
Short Percent 6.42% 48% F 31% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.